AUR vs KOD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AUR is the larger of the two ($9.14B market cap): the incumbent the market prices for continued execution (-9.63x forward earnings, beta 2.87). KOD is the smaller challenger ($6.65B), priced similarly on forward earnings (-30.79x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

AUR vs KOD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAURKODWhat it tells you
Market cap$9.14B$6.65BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-9.63-30.79Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.871.98Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range19% of range97% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.08108.61How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how AUR and KOD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AUR and KOD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AUR and KOD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Aurora Innovation (AUR) do?

Aurora Innovation, led by self-driving pioneer Chris Urmson, builds the Aurora Driver, a combination of software, sensors, and compute that lets Class 8 trucks operate without a human behind the wheel. The company does not own the trucks; instead it partners with truck makers such as PACCAR and Volvo and with carriers and shippers, aiming to earn revenue on a per-mile or driver-as-a-service basis as it removes the cost and constraints of human drivers from long-haul freight. The path to meaningful revenue depends on expanding the number of driverless trucks running on commercial routes, then adding lanes across the Sun Belt and beyond.

Full AUR guide

What does Kodiak Sciences (KOD) do?

Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degeneration (wet AMD), and macular edema. Its programs are built on an antibody biopolymer conjugate (ABC) platform intended to extend how long a single injection lasts in the eye. The lead candidate, tarcocimab tedromer (branded Zenkuda), delivered positive Phase 3 GLOW2 data in diabetic retinopathy in early 2026. Then, on September 29, 2026, Kodiak reported that the Phase 3 DAYBREAK study in wet AMD met its primary endpoint in both arms: Zenkuda and tabirafusp-ted (formerly KSI-501, an anti-IL-6 and VEGF-trap bispecific) were each non-inferior to Regeneron's Eylea (aflibercept) on vision at one year. In the Zenkuda arm, 54% of patients reached a six-month dosing interval, with no intraocular inflammation reported. Kodiak plans a multi-indication BLA for Zenkuda in Q4 2026 covering wet AMD, diabetic retinopathy, and macular edema after retinal vein occlusion, and further readouts (PEAK and PINNACLE for KSI-101 in inflammatory macular edema, ALTO for tabirafusp-ted in diabetic macular edema) are still ahead.

Full KOD guide

AUR vs KOD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • AUR drivers: First-mover commercial lead; Asset-light, partner-driven model.
  • KOD drivers: Multi-indication Phase 3 pipeline; Durability-focused ABC platform.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Aurora is essentially a pre-revenue company: it generated about $5 million of revenue over the last twelve months and a net loss of roughly $900 million, with operating cash outflow of about $679 million. For KOD, kodiak is still pre-revenue, and positive Phase 3 data does not guarantee FDA approval; the BLA has not yet been filed and a review typically takes about a year.

AUR or KOD: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AUR if you believe its drivers more; KOD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AUR and KOD guides.

AUR vs KOD: the full fundamentals

AUR. A pre-revenue autonomy company cannot be valued on earnings or a normal price-to-sales ratio: at about $10.5 billion, AUR trades at more than 2,000 times trailing revenue. The numbers that matter are cash burn against the roughly $1.22 billion cash cushion, and progress toward the 30,000-truck, $5 billion revenue goal for 2030. Third-quarter results on October 28, 2026 (consensus revenue about $2.9 million) are the next read on both.

KOD. Kodiak has no product revenue and posts steady net losses, so earnings multiples do not apply and valuation reflects pipeline expectations. After DAYBREAK the market capitalization rose from about $1.3 billion in July to roughly $5.6 billion, now pricing in a meaningful probability of approval and a commercial launch. Cash of about $126 million at mid-2026 is small next to that valuation and to the cost of a launch, so financing remains a live question; Q3 results are expected around November 12.

Headline figures (approximate, October 2026): AUR shows revenue (ttm) About $5 million (Q2 2026 about $2 million), net loss (ttm) About $900 million (Q2 2026 about $270 million), eps, latest quarter -$0.14 vs -$0.12 expected (Q2 2026), forward p/e Not meaningful (2026 EPS estimate about -$0.49); KOD shows revenue (ttm) ~$0 (no approved products), net loss (ttm) ~$242M, net loss (q2 2026) ~$66M, eps (q2 2026, actual vs est.) -$1.05 vs -$0.96.

The bottom line: AUR vs KOD

AUR and KOD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AUR and KOD exposure against your real portfolio. It is not an investment adviser.

Wondering how AUR or KOD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Aurora Innovation

Ask Walnut's AI anything about AUR and see how it fits what you own.

FAQ

What is the difference between AUR and KOD?

+

Aurora Innovation, led by self-driving pioneer Chris Urmson, builds the Aurora Driver, a combination of software, sensors, and compute that lets Class 8 trucks operate without a human behind the wheel. Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degeneration (wet AMD), and macular edema. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AUR or KOD the better stock?

+

Neither is universally better. AUR is the larger incumbent; KOD is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AUR or KOD?

+

On forward P/E (as of November 2026), AUR trades at -9.63x and KOD at -30.79x, so KOD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AUR and KOD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AUR vs KOD?

+

AUR: Aurora is essentially a pre-revenue company: it generated about $5 million of revenue over the last twelve months and a net loss of roughly $900 million, with operating cash outflow of about $679 million. Losses are widening, from about $201 million in the third quarter of 2025 to about $270 million in the second quarter of 2026, and that quarter's loss per share of $0.14 missed the $0.12 estimate. With about $1.22 billion in cash, it will likely raise additional capital, and Aurora has used at-the-market equity programs that dilute existing shareholders. Execution risk is high: scaling from a few trucks toward the 30,000-truck 2030 goal requires flawless safety performance, and a single serious driverless accident could trigger regulatory or reputational setbacks. Autonomous-vehicle regulation remains a patchwork that could slow expansion outside Texas, even with the October 2026 warning-device waiver. Competition is intensifying from Kodiak, Gatik, Waabi, Plus, and Einride in trucking and from far better-funded robotaxi players like Waymo and Tesla. Finally, the stock trades on a roughly $10 billion valuation built almost entirely on future expectations, so any delay in the deployment timeline can drive sharp drawdowns, as the 17% drop in the month to October 16, 2026 showed. KOD: Kodiak is still pre-revenue, and positive Phase 3 data does not guarantee FDA approval; the BLA has not yet been filed and a review typically takes about a year. The 2021 wet AMD failure is a reminder of how sharply the stock can move on a single event, and after a roughly 242% gain in 2026 the shares already price in a good deal of success (one valuation model cited in October headlines called them modestly overvalued). A first commercial launch would face entrenched competitors including Regeneron's Eylea franchise and Roche's Vabysmo, plus lower-cost off-label and biosimilar options. The company burns cash (net loss of about $66 million in Q2 2026, with cash of roughly $126 million at June 30), so additional dilutive financing is a realistic possibility. Ophthalmology commercialization is capital-intensive, and durability claims must hold up in real-world use to justify premium positioning.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AUR or KOD; figures are approximate and dated (as of November 2026). Verify current data before investing.